|
| Tuesday, December 26, 2023 |
|
|
大分大学とエーザイ、リストバンド型生体センサを用いた脳内アミロイドベータ蓄積予測モデルの開発 |
| more info >> |
|
| Tuesday, December 19, 2023 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, ?tasurgratinib?) for biliary tract cancer with FGFR2 gene fusion. more info >> |
|
| Thursday, December 14, 2023 |
|
|
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement |
| Eisai Co., Ltd. and Mizuho Bank, Ltd. announced today that the companies have signed a sustainability-linked syndicated loan agreement, which comes into effect today. more info >> |
|
|
"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI Intravenous Infusion" (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List. more info >> |
|
| Monday, December 11, 2023 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. more info >> |
|
| Thursday, November 30, 2023 |
|
|
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand |
| Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer's disease (AD) in Thailand. more info >> |
|
| Wednesday, November 22, 2023 |
|
|
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting |
| Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orland, Florida and virtually from December 1-5, 2023. more info >> |
|
| Monday, November 20, 2023 |
|
|
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023 |
| Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline. more info >> |
|
| Wednesday, October 25, 2023 |
|
|
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023 |
| Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category. more info >> |
|
| Monday, October 16, 2023 |
|
|
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai Co. Ltd announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference. more info >> |
|
|
|
|
